Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present an update on the company’s advancements at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 p.m. ET in Boston, MA. The presentation will be accessible via a live webcast on the company’s investor relations page, with a replay available for 90 days post-event.

Black Diamond specializes in precision oncology, focusing on MasterKey therapies targeting oncogenic driver mutations in genetically-defined cancers, including its lead programs BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma, and BDTX-4933 targeting RAF mutations.

CAMBRIDGE, Mass. and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey therapies targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Cowen 43^rd Annual Health Care Conference on Monday, March 6, 2023, at 12:50 p.m. ET in Boston, MA.

A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

About Black Diamond

Black Diamond Therapeutics is a clinical-stage precision oncology medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Black Diamond leverages a deep understanding of cancer genetics and onco-protein structure and function, to discover and develop innovative MasterKey therapies. The Company’s MasterKey therapies are designed to overcome resistance, minimize on-target, wild-type mediated toxicities, and be brain penetrant to address significant unmet medical needs of patients with genetically defined cancers. The Company is advancing a robust pipeline with lead clinical-stage program BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive non-small cell lung cancer (NSCLC) and in glioblastoma multiforme (GBM), and BDTX-4933, a program targeting RAF MasterKey mutations in solid tumors, as well as discovery-stage research programs. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate MasterKey mutations.

Contact:
Julie Seidel, Stern Investor Relations
(212) 362-1200
investors@bdtx.com
media@bdtx.com

FAQ

What will Black Diamond Therapeutics present at the Cowen Conference?

Black Diamond Therapeutics will present an update on its progress, led by CEO David M. Epstein, on March 6, 2023.

When is Black Diamond Therapeutics' presentation at the Cowen 43rd Annual Health Care Conference?

The presentation is scheduled for March 6, 2023, at 12:50 p.m. ET.

How can I watch the Black Diamond Therapeutics presentation?

The presentation will be available via a live webcast on the company’s investor relations website.

What are the lead programs of Black Diamond Therapeutics?

Black Diamond's lead programs include BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma, and BDTX-4933 targeting RAF mutations.

What is the focus of Black Diamond Therapeutics?

Black Diamond Therapeutics focuses on developing MasterKey therapies targeting oncogenic mutations in genetically-defined cancers.